Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals Management Change

Lincoln Pharmaceuticals announced the resignation of Mr. Manoj Rai, Sr. General Manager (Head QA), a Senior Management Personnel. He departs effective 24 September 2026 for personal reasons.

Lincoln Pharmaceuticals Other Announcement

Lincoln Pharmaceuticals has dispatched physical letters to shareholders with unregistered email IDs to provide access to the Annual Report for FY 2025-26 and facilitate KYC updates.

Lincoln Pharmaceuticals Annual Report

Lincoln Pharmaceuticals submitted its Annual Report for FY 2025-26 and notice for the 32nd Annual General Meeting scheduled for September 30, 2026.

Lincoln Pharmaceuticals Dividend

Lincoln Pharmaceuticals declared a final dividend of ₹1.80 per equity share for FY 2025-26. The 32nd AGM is scheduled for September 30, 2026.

Lincoln Pharmaceuticals Annual General Meeting

Lincoln Pharmaceuticals announced its 32nd AGM for September 30, 2026, and book closure dates from September 12 to 30, 2026, to determine dividend entitlement.

Lincoln Pharmaceuticals Q1 FY27 Results: Net Profit ₹36.2 Cr, Up 30.7% YoY

Lincoln Pharmaceuticals Ltd reported revenue from operations of ₹177.3 Cr (+15.1% YoY) and net profit of ₹36.2 Cr (+30.7% YoY) for Q1 FY27.

Key figure

Net profit ₹36.2 Cr · +30.7% YoY

Lincoln Pharmaceuticals Board Meeting Date

Lincoln Pharmaceuticals Ltd will hold a board meeting on August 13, 2026. The board will consider and approve unaudited financial results for the quarter ended June 2026.